BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

• Sponsor: M.D. Anderson Cancer Center (Other)
• Overall Status: Completed
• CT.gov ID: NCT01263782
• Collaborator: Eli Lilly and Company (Industry), Genentech, Inc. (Industry)
• Enrollment: 64
• Location: 1
• Arms: 4
• Actual Duration (Months): 75
• Patients Per Site Per Month: 0.9

Study Details

Study Description

Brief Summary

The goal of this clinical research study is to learn if knowing biomarker status can help researchers find better treatment combinations for patients with advanced NSCLC.

Researchers want to use biomarker status to decide what drug (bevacizumab, or cixutumumab) to give in combination with carboplatin and pemetrexed. The safety of these drug combinations will also be studied.

Condition or Disease	Intervention/Treatment	Phase
Lung Cancer	Drug: Carboplatin; Drug: Pemetrexed; Drug: Bevacizumab; Drug: Cixutumumab	Phase 2

Detailed Description

The Study Drugs:

Carboplatin is designed to interfere with the growth of cancer cells by stopping cell division, which may cause the cells to die.

Pemetrexed is designed to block enzymes in the body that play a part in tumor growth.

Bevacizumab is designed to block the growth of blood vessels that supply nutrients necessary for tumor growth. This may prevent or slow down the growth of cancer cells.

Cixutumumab is a monoclonal antibody, which means that it attaches to specific targets on cancer cells. These targets are called IGF-1R and help the cancer cells grow and divide. Cixutumumab is designed to block these receptors on tumor cells that may cause tumors to grow.

Study Groups and Drug Administration (Combination Therapy):

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the roll of dice) to 1 of 3 groups. You will have an equal chance of being assigned to each group. Each cycle is 21 days (+/- 5 days).

• If you are in Group 1, you will receive carboplatin and pemetrexed on Day 1 of each cycle. Carboplatin will be given by vein over 10 minutes. Pemetrexed will be given by vein over 30 minutes.

• If you are in Group 2, you will receive bevacizumab, carboplatin, and pemetrexed on Day 1 of each cycle. Bevacizumab will be given by vein over about 90 minutes for the first dose, about 60 minutes for the second dose, and about 30 minutes for all other doses. Carboplatin will be given by vein over 10 minutes. Pemetrexed will be given by vein over 30 minutes.

• If you are in Group 3, you will receive cixutumumab, carboplatin, and pemetrexed on Day 1 of each cycle. Cixutumumab is given by vein over 60 minutes. Carboplatin will be given by vein over 10 minutes. Pemetrexed will be given by vein over 30 minutes.

Study Visits During Combination Therapy:

If you are in Group 3, before you begin receiving study drugs, you will have a hearing test.

On Day 1 (+/- 5 days) of Cycles 1, 2, and 4:

• You will have a physical exam, including measurement of your weight and vital signs.

• You will be asked about any drugs you may be taking and any side effects you may be having.

• Your performance status will be recorded.

• Blood (about 3 teaspoons) will be drawn for routine tests.

• If you are in Group 2, urine will be collected for routine tests.

On Days 8 and 15 of Cycle 1:

°If you are in Group 3, blood (about 1 teaspoon) will be drawn for routine tests.

On Day 1 of Cycle 3:

• You will have a physical exam, including measurement of your weight and vital signs.

• You will be asked about any drugs you may be taking and any side effects you may be having.

• Your performance status will be recorded.

• Blood (about 3 teaspoons) will be drawn for routine tests.

• You will have a CT scan and/or MRI scan of the chest (and abdomen if the doctor thinks it is needed) to check the status of the disease.

• You will have an MRI scan of the brain.

• You will have a chest x-ray to check the status of the disease.

• If you are in Group 2, urine will be collected for routine tests.

At any time your doctor thinks it may be needed, blood (about 1 teaspoon) will be drawn to check how well your blood clots.

Maintenance Therapy:

After you have completed 4 cycles of combination therapy, you may be eligible for maintenance therapy.

If you are in Group 1,you will receive pemetrexed by vein over 10 minutes on Day 1 (± 5 days) of every 21-day cycle.

If you are in Group 2, you will receive pemetrexed by vein over 10 minutes and bevacizumab over about 30 minutes on Day 1 (± 5 days) of every 21-day cycle.

If you are in Group 3, you will receive pemetrexed by vein over about 10 minutes and cixutumumab by vein over about 60 minutes on Day 1 (± 5 days) of every 21-day cycle.

Study Visits During Maintenance Therapy:

On Day 1 of each cycle:

• You will have a physical exam, including measurement of your weight and vital signs.

• You will be asked about any drugs you may be taking and any side effects you may be having.

• Your performance status will be recorded.

• Blood (about 3 teaspoons) will be drawn for routine tests.

• You will have a CT scan and/or MRI scan of the chest (and abdomen if the doctor thinks it is needed) to check the status of the disease.

• You will have an MRI scan of the brain.

• You will have a chest x-ray to check the status of the disease.

• If you are in Group 2, urine will be collected for routine tests.

Length of Study:

You may continue taking the study drug(s) for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drug if the disease gets worse or intolerable side effects occur.

Your participation on the study will be over once you have completed the end-of-dosing visit and follow-up.

End-of-Dosing Visit:

When you go off study for any reason, you will have an end-of-dosing visit. The following tests and procedures will be performed:

• Your medical history will be recorded.

• You will have a complete physical exam, including measurement of your weight and vital signs.

• You will be asked about any drugs you may be taking and any side effects you may be having.

• Your performance status will be recorded.

• Blood (about 3 teaspoons) and urine will be collected for routine tests.

• You will have a CT scan and/or MRI of the chest (and abdomen if the doctor thinks it is needed) to check the status of the disease.

• You will have an MRI scan of the brain.

• You will have a chest x-ray.

• You will have an ECG.

• If you are in Group 3, you will have a hearing test.

Follow-Up:

You will have follow-up every 4 weeks after you are no longer taking the study drugs. You will be contacted at a clinic visit or by phone. You will be called every 3 months for up to 3 years and asked about any cancer treatments you may be receiving. This phone call should take about 10 minutes.

This is an investigational study. Carboplatin and pemetrexed are FDA approved and commercially available for the treatment of certain types of NSCLC. Bevacizumab is FDA approved and commercially available for treatment of certain types of colon or rectal cancer, NSCLC, and renal cell carcinoma. Cixutumumab is not FDA approved or commercially available. At this time, cixutumumab is only being used in research.

Up to 225 patients will take part in this study. All will be enrolled at MD Anderson.

Study Design

• Study Type: Interventional
• Actual Enrollment: 64 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting
• Actual Study Start Date: May 17, 2011
• Actual Primary Completion Date: Aug 15, 2017
• Actual Study Completion Date: Aug 15, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Carboplatin + Pemetrexed The chemotherapy will be Carboplatin (AUC 6) and Pemetrexed (500 mg/m2) every 3 weeks for 4 cycles. Then maintenance Pemetrexed (500 mg/m2 every 3 weeks) will be administered until disease progression or excessive toxicity. If patients are randomized into one of the arms with a biologic therapy, patients will take the chemotherapy prescribed above, but will also receive the biologic therapy during the same time period.	Drug: Carboplatin; AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.; Other Names: Paraplatin ; Drug: Pemetrexed; 500 mg/m2 by vein on day 1 of each 21 day cycle.; Other Names: LY231514 Alimta MTA Multitargeted Antifolate NSC-698037
Experimental: Chemo (Carbo/Peme) + Bevacizumab Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle. Bevacizumab 15 mg/kg by vein on day 1 of each 21 day cycle.	Drug: Carboplatin; AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.; Other Names: Paraplatin ; Drug: Pemetrexed; 500 mg/m2 by vein on day 1 of each 21 day cycle.; Other Names: LY231514 Alimta MTA Multitargeted Antifolate NSC-698037 ; Drug: Bevacizumab; 15 mg/kg by vein on day 1 of each 21 day cycle.; Other Names: Avastin Anti-VEGF monoclonal antibody rhuMAb-VEGF
Experimental: Chemo (Carbo/Peme) Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.	Drug: Carboplatin; AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.; Other Names: Paraplatin ; Drug: Pemetrexed; 500 mg/m2 by vein on day 1 of each 21 day cycle.; Other Names: LY231514 Alimta MTA Multitargeted Antifolate NSC-698037
Experimental: Chemo (Carbo/Peme) + Cixutumumab Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle. Cixutumumab 20 mg/kg by vein on day 1 of each 21 day cycle.	Drug: Carboplatin; AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.; Other Names: Paraplatin ; Drug: Pemetrexed; 500 mg/m2 by vein on day 1 of each 21 day cycle.; Other Names: LY231514 Alimta MTA Multitargeted Antifolate NSC-698037 ; Drug: Cixutumumab; 20 mg/kg by vein on day 1 of each 21 day cycle.; Other Names: IMC-A12

Outcome Measures

Primary Outcome Measures

1. Progression Free Survival [From treatment start to the time of progression or death, whichever occurred first, or to the time of last contact, assessed up to 5 years]

   It is defined as from treatment start to the time of progression or death, whichever occurred first, or to the time of last contact. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Secondary Outcome Measures

1. Overall Response Rate [From treatment start to every two cycles of completed therapy.]

   Tumor response was assessed every two cycles of completed therapy. Responses will be based on a comparison to the pretreatment tumor evaluation. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. The patient has a diagnosis of pathologically confirmed nonsquamous (nonpredominant squamous) NSCLC by tumor biopsy and/or fine-needle aspiration. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the patient is ineligible.

2. The patient has a diagnosis of either stage IIIB or stage IV NSCLC or has recurrent NSCLC and is not a candidate for curative treatment. Patients may not have had chemotherapy for the advanced setting.

3. The patient has measurable NSCLC.

4. The patient's Eastern Cooperative Oncology Group (ECOG) performance status is </=2 at study entry.

5. The patient should have tumor available for epidermal growth factor receptor (EGFR) mutations, ALK fusions and other molecular analyses. If there is no tissue then the patient has should have biopsy accessible tumor.

6. The patient has adequate hematologic function as defined by an absolute neutrophil count (ANC) >/= 1,500/mm^{3, platelet count >/= 100,000/mm}3, white blood cell count (WBC) >/= 3,000/ mm^3, and hemoglobin >/= 9 g/dL.

7. The patient has adequate hepatic function as defined by a total bilirubin level </= 1.5 X the upper limit of normal (Serum bilirubin >/= 1.5x Upper Limit of Normal in the setting of known Gilbert's disease is allowed), and alkaline phosphatase, AST and ALT </= 2.5 X the upper limit of normal or </= 5.0 x ULN if liver metastases are present.

8. The patient has adequate renal function as defined as CrCl of at least 45ml/min.

9. If patient has brain metastasis, they must have been stable (treated and/or asymptomatic) and off steroids for at least 2 weeks.

10. The patient is >/= 18 years of age.

11. The patient has signed informed consent.

12. Pregnancy Test. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation and for six (6) months after discontinuation of the study drugs. Childbearing potential will be defined as women who have had menses within the past 12 months, who have not had tubal ligation, hysterectomy or bilateral oophorectomy. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately. The patient, if a man, agrees to use effective contraception or abstinence for the duration of study participation and for six (6) months after discontinuation of the study drugs.

13. The ability to interrupt the use of NSAIDS two days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of Pemetrexed.

Exclusion Criteria:

1. The patient has received prior definitive therapy (chemotherapy, surgery, or radiotherapy) within 3 months of initiating study drug or within, 2 weeks of localized palliative radiotherapy. Patients treated with initial biologic therapy that progress are eligible (no drug within 4 weeks). Patients must have recovered from the acute toxic effects prior to Day 1 of Cycle 1 to grade </= 1 or baseline.

2. Patients may not have had prior chemotherapy for first line treatment for NSCLC Stage IIIB/IV. Patient with activating EGFR mutations could have been treated with an EGFR tyrosine kinase inhibitor. Similarly patient with ALK or ROS1 fusions could have had treatment with crizotinib or other ALK inhibitors. Patients may not have had prior biologic therapy with antibodies targeting VEGF,or insulin-like growth factor receptor (IGFR).

3. The patient has undergone prior thoracic or abdominal surgery within 30 days of study entry, excluding prior diagnostic biopsy.

4. The patient has a history of uncontrolled angina, arrhythmias, or congestive heart failure.

5. The patient has inadequately controlled hypertension (defined as systolic blood pressure > 140 and/or diastolic > 90 mm Hg on antihypertensive medications).

6. The patient has a history of stroke or transient ischemic attack within 6 months prior to Day 1 of Cycle 1.

7. The patient is unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone according to protocol.

8. The patient has neuropathy >/= grade 2.

9. The patient has a history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis.

10. The patient is currently receiving ongoing treatment with full-dose warfarin or equivalent (that is, unfractionated and/or low molecular weight heparin).

11. The patient is pregnant.

12. The patient is breastfeeding.

13. Presence of significant third space fluid which cannot be controlled by drainage.

14. The patient's tumor harbors the EML4-ALK fusion gene.

15. Drug Specific Eligibility for Treatment Arms. Patients are excluded from the Bevacizumab arm if they have a history of hemoptysis (>/= ½ teaspoon of bright red blood per episode) within 3 months prior to randomization.

16. Drug Specific Eligibility for Treatment Arms. Patients are excluded from Bevacizumab arm if the Urine Protein Creatinine (UPC) ratio is not within the institutional normal limits.

17. Drug Specific Eligibility for Treatment Arms. Patients are excluded from the IMC-A12 containing arm if they have poorly controlled diabetes: HBA1C>8% or if the patient has abnormally elevated fasting serum glucose (defined >110% ULN).

18. Drug Specific Eligibility for Treatment Arms. Patients are excluded if they have known hypersensitivity to any of the drugs.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Texas MD Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• M.D. Anderson Cancer Center
• Eli Lilly and Company
• Genentech, Inc.

Investigators

• Principal Investigator: George Simon, MD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Mar 7, 2013

More Information

Additional Information:

• University of Texas MD Anderson Cancer Center Website

Publications

None provided.

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT01263782
• Other Study ID Numbers: 2010-0097; NCI-2011-00301
• First Posted: Dec 21, 2010
• Last Update Posted: May 15, 2019
• Last Verified: May 1, 2019

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by M.D. Anderson Cancer Center: Non-Small Cell Lung Cancer; NSCLL; Nonsquamous cell; Metastatic disease; Cixutumumab; IMC-A12; Carboplatin; Paraplatin; Pemetrexed; LY231514; Alimta; MTA; Multitargeted Antifolate; NSC-698037; Bevacizumab; Avastin; Anti-VEGF monoclonal antibody; rhuMAb-VEGF
• Additional relevant MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Bevacizumab; Carboplatin; Pemetrexed

Study Results

Participant Flow

Recruitment Details	Twenty-four patients with non-small cell lung cancer were recruited from June 2011 to October 2013 at the University of Texas MD Anderson Cancer Center.
Pre-assignment Detail	The patients had pre-treatment evaluations, which were used to determine the patients' study eligibility, within 4 weeks prior to initiating therapy. Out of 64 participants, 40 was screen failed.

Arm/Group Title	Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe	Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance	Carboplatin + Pemetrexed + Cetuximab Followed by Maintenance P	Carboplatin + Pemetrexed + Cixutumumab Followed by Maintenance
Arm/Group Description	Four 21-day cycles of combination AUC 6 of carboplatin and 500 mg/m2 of pemetrexed; maintenance pemetrexed and pemetrexed every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 15 mg/kg of bevacizumab; maintenance pemetrexed and bevacizumab every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 250 mg/m2 of cetuximab (400mg/m2 on Cycle 1, Day 1 only); maintenance pemetrexed and cetuximab every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 20 mg/kg of cixutumumab; maintenance pemetrexed and cixutumumab every 21 days until disease progression
Period Title: Overall Study
STARTED	6	6	6	6
COMPLETED	6	6	3	5
NOT COMPLETED	0	0	3	1

Baseline Characteristics

Arm/Group Title	Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe	Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance	Carboplatin + Pemetrexed + Cetuximab Followed by Maintenance P	Carboplatin + Pemetrexed + Cixutumumab Followed by Maintenance	Total
Arm/Group Description	Four 21-day cycles of combination AUC 6 of carboplatin and 500 mg/m2 of pemetrexed; maintenance pemetrexed and pemetrexed every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 15 mg/kg of bevacizumab; maintenance pemetrexed and bevacizumab every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 250 mg/m2 of cetuximab (400mg/m2 on Cycle 1, Day 1 only); maintenance pemetrexed and cetuximab every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 20 mg/kg of cixutumumab; maintenance pemetrexed and cixutumumab every 21 days until disease progression	Total of all reporting groups
Overall Participants	6	6	6	6	24
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%	0 0%	0 0%
Between 18 and 65 years	3 50%	3 50%	3 50%	2 33.3%	11 45.8%
>=65 years	3 50%	3 50%	3 50%	4 66.7%	13 54.2%
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	66	65	68	68	66
Sex: Female, Male (Count of Participants)
Female	3 50%	1 16.7%	3 50%	0 0%	7 29.2%
Male	3 50%	5 83.3%	3 50%	6 100%	17 70.8%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%	0 0%	0 0%
Not Hispanic or Latino	1 16.7%	2 33.3%	0 0%	0 0%	3 12.5%
Unknown or Not Reported	5 83.3%	4 66.7%	6 100%	6 100%	21 87.5%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%	0 0%
Asian	0 0%	1 16.7%	0 0%	1 16.7%	2 8.3%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%
Black or African American	1 16.7%	0 0%	1 16.7%	1 16.7%	3 12.5%
White	5 83.3%	5 83.3%	5 83.3%	4 66.7%	19 79.2%
More than one race	0 0%	0 0%	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	0 0%
Region of Enrollment (participants) [Number]
United States	6 100%	6 100%	6 100%	6 100%	24 100%

Outcome Measures

1. Primary Outcome

Title	Progression Free Survival
Description	It is defined as from treatment start to the time of progression or death, whichever occurred first, or to the time of last contact. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time Frame	From treatment start to the time of progression or death, whichever occurred first, or to the time of last contact, assessed up to 5 years

Outcome Measure Data

Analysis Population Description

Patients who had treatment

Arm/Group Title	Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe	Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance	Carboplatin + Pemetrexed + Cetuximab Followed by Maintenance P	Carboplatin + Pemetrexed + Cixutumumab Followed by Maintenance
Arm/Group Description	Four 21-day cycles of combination AUC 6 of carboplatin and 500 mg/m2 of pemetrexed; maintenance pemetrexed and pemetrexed every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 15 mg/kg of bevacizumab; maintenance pemetrexed and bevacizumab every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 250 mg/m2 of cetuximab (400mg/m2 on Cycle 1, Day 1 only); maintenance pemetrexed and cetuximab every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 20 mg/kg of cixutumumab; maintenance pemetrexed and cixutumumab every 21 days until disease progression
Measure Participants	6	6	6	6
Median (95% Confidence Interval) [month]	5.2	14.5	20.6	8

2. Secondary Outcome

Title	Overall Response Rate
Description	Tumor response was assessed every two cycles of completed therapy. Responses will be based on a comparison to the pretreatment tumor evaluation. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time Frame	From treatment start to every two cycles of completed therapy.

Outcome Measure Data

Analysis Population Description

Patients who were evaluable for response

Arm/Group Title	Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe	Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance	Carboplatin + Pemetrexed + Cetuximab Followed by Maintenance P	Carboplatin + Pemetrexed + Cixutumumab Followed by Maintenance
Arm/Group Description	Four 21-day cycles of combination AUC 6 of carboplatin and 500 mg/m2 of pemetrexed; maintenance pemetrexed and pemetrexed every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 15 mg/kg of bevacizumab; maintenance pemetrexed and bevacizumab every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 250 mg/m2 of cetuximab (400mg/m2 on Cycle 1, Day 1 only); maintenance pemetrexed and cetuximab every 21 days until disease progression	Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 20 mg/kg of cixutumumab; maintenance pemetrexed and cixutumumab every 21 days until disease progression
Measure Participants	6	6	6	6
No change/Stable Disease	5 83.3%	3 50%	2 33.3%	3 50%
Partial Remission	0 0%	3 50%	1 16.7%	2 33.3%
Progressive Disease	1 16.7%	0 0%	0 0%	0 0%

Adverse Events

Time Frame	Through study completion, an average of 3 years
Adverse Event Reporting Description	Patients who were evaluable for toxicity and grades 1-3 adverse events.
Arm/Group Title	Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe		Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance		Carboplatin + Pemetrexed + Cetuximab Followed by Maintenance P		Carboplatin + Pemetrexed + Cixutumumab Followed by Maintenance
Arm/Group Description	Four 21-day cycles of combination AUC 6 of carboplatin and 500 mg/m2 of pemetrexed; maintenance pemetrexed and pemetrexed every 21 days until disease progression		Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 15 mg/kg of bevacizumab; maintenance pemetrexed and bevacizumab every 21 days until disease progression		Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 250 mg/m2 of cetuximab (400mg/m2 on Cycle 1, Day 1 only); maintenance pemetrexed and cetuximab every 21 days until disease progression		Four 21-day cycles of combination AUC 6 of carboplatin, 500 mg/m2 of pemetrexed, and 20 mg/kg of cixutumumab; maintenance pemetrexed and cixutumumab every 21 days until disease progression
All Cause Mortality
	Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe		Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance		Carboplatin + Pemetrexed + Cetuximab Followed by Maintenance P		Carboplatin + Pemetrexed + Cixutumumab Followed by Maintenance
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/6 (16.7%)		0/6 (0%)		0/3 (0%)		0/5 (0%)
Serious Adverse Events
	Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe		Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance		Carboplatin + Pemetrexed + Cetuximab Followed by Maintenance P		Carboplatin + Pemetrexed + Cixutumumab Followed by Maintenance
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/6 (33.3%)		0/6 (0%)		2/3 (66.7%)		0/5 (0%)
Cardiac disorders
Cardiac arrest	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Infections and infestations
Sepsis	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Urinary tract infection	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Investigations
Creatinine increased	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Metabolism and nutrition disorders
Hypercalcemia	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Hyperglycemia	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Respiratory, thoracic and mediastinal disorders
Pneumonitis	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Surgical and medical procedures
Other, Endarterectomy	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Other (Not Including Serious) Adverse Events
	Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe		Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance		Carboplatin + Pemetrexed + Cetuximab Followed by Maintenance P		Carboplatin + Pemetrexed + Cixutumumab Followed by Maintenance
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	6/6 (100%)		6/6 (100%)		3/3 (100%)		4/5 (80%)
Blood and lymphatic system disorders
Anemia	3/6 (50%)	8	3/6 (50%)	6	2/3 (66.7%)	6	4/5 (80%)	8
Blood and lymphatic system disorders - Other, specify	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Cardiac disorders
CAD	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Chest pain - cardiac	1/6 (16.7%)	1	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Myocardial infarction	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Ear and labyrinth disorders
Hearning Loss	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Eye disorders
Watering eyes	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Gastrointestinal disorders
Abdominal pain	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Billary tract infection (cholendocholithiasis)	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Constipation	3/6 (50%)	3	2/6 (33.3%)	2	1/3 (33.3%)	1	2/5 (40%)	2
Diarrhea	1/6 (16.7%)	1	1/6 (16.7%)	2	1/3 (33.3%)	1	1/5 (20%)	3
Diverticulosis	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Dry mouth	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Dyspepsia	0/6 (0%)	0	1/6 (16.7%)	1	1/3 (33.3%)	1	0/5 (0%)	0
Dysphagia	0/6 (0%)	0	1/6 (16.7%)	3	0/3 (0%)	0	0/5 (0%)	0
Esophageal obstruction	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Esophagitis	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Gastroesophageal reflux disease	0/6 (0%)	0	2/6 (33.3%)	2	0/3 (0%)	0	0/5 (0%)	0
Mucositis oral	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	1/5 (20%)	1
Nausea	2/6 (33.3%)	3	4/6 (66.7%)	4	1/3 (33.3%)	1	1/5 (20%)	1
Oral pain	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Vomiting	1/6 (16.7%)	1	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
General disorders
Abrasions to RUE.	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Edema face	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Edema limbs	1/6 (16.7%)	1	1/6 (16.7%)	2	2/3 (66.7%)	2	1/5 (20%)	3
Edema trunk	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Fatigue	4/6 (66.7%)	5	4/6 (66.7%)	4	3/3 (100%)	3	4/5 (80%)	5
Fever	3/6 (50%)	4	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Gait disturbance	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Infusion related reaction	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Pain	1/6 (16.7%)	1	4/6 (66.7%)	4	1/3 (33.3%)	1	2/5 (40%)	2
Immune system disorders
Anaphylaxis	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Infections and infestations
Bladder infection	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Laryngitis	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Lung infection	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Paronychia	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Upper respiratory infection	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Urinary tract infection	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Vaginal infection	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Investigations
Alanine aminotransferase increased	1/6 (16.7%)	1	1/6 (16.7%)	2	0/3 (0%)	0	1/5 (20%)	2
Alkaline phosphatase increased	1/6 (16.7%)	1	1/6 (16.7%)	1	0/3 (0%)	0	1/5 (20%)	2
Aspartate aminotransferase increased	1/6 (16.7%)	1	1/6 (16.7%)	1	1/3 (33.3%)	1	1/5 (20%)	1
Blood bilirubin increased	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Cholesterol high	0/6 (0%)	0	2/6 (33.3%)	2	0/3 (0%)	0	1/5 (20%)	1
Creatinine increased	0/6 (0%)	0	2/6 (33.3%)	2	2/3 (66.7%)	4	1/5 (20%)	1
Elevated LDH	0/6 (0%)	0	1/6 (16.7%)	2	0/3 (0%)	0	0/5 (0%)	0
Hemoglobin increased	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Neutrophil count decreased	1/6 (16.7%)	4	2/6 (33.3%)	3	1/3 (33.3%)	2	1/5 (20%)	1
Platelet count decreased	1/6 (16.7%)	2	3/6 (50%)	4	1/3 (33.3%)	1	1/5 (20%)	1
Weight loss	0/6 (0%)	0	2/6 (33.3%)	2	0/3 (0%)	0	3/5 (60%)	3
White blood cell decreased	0/6 (0%)	0	2/6 (33.3%)	2	0/3 (0%)	0	1/5 (20%)	1
Metabolism and nutrition disorders
Anorexia	0/6 (0%)	0	2/6 (33.3%)	2	1/3 (33.3%)	1	3/5 (60%)	5
Hypercalcemia	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	3	0/5 (0%)	0
Hyperglycemia	2/6 (33.3%)	10	1/6 (16.7%)	3	1/3 (33.3%)	1	3/5 (60%)	7
Hyperkalemia	1/6 (16.7%)	1	0/6 (0%)	0	1/3 (33.3%)	3	1/5 (20%)	1
Hypernatremia	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Hyperuricemia	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	4
Hypoalbuminemia	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	2/5 (40%)	2
Hypocalcemia	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	5	1/5 (20%)	1
Hypokalemia	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	2/5 (40%)	4
Hypomagnesemia	3/6 (50%)	6	2/6 (33.3%)	2	3/3 (100%)	12	2/5 (40%)	2
Hyponatremia	1/6 (16.7%)	2	1/6 (16.7%)	1	0/3 (0%)	0	2/5 (40%)	2
Increasse LDH	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Musculoskeletal and connective tissue disorders
Arthralgia	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Arthritis	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Back pain	0/6 (0%)	0	1/6 (16.7%)	1	1/3 (33.3%)	1	0/5 (0%)	0
Chest wall pain	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Generalized muscle weakness	2/6 (33.3%)	2	1/6 (16.7%)	1	1/3 (33.3%)	1	0/5 (0%)	0
Muscle weakness lower limb	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Myalgia	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
swelling both hands	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	1/5 (20%)	1
Nervous system disorders
Dizziness	1/6 (16.7%)	3	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Dysesthesia	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Dysgeusia	1/6 (16.7%)	2	1/6 (16.7%)	1	0/3 (0%)	0	2/5 (40%)	2
Edema (Brain-cerebral)	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Peripheral sensory neuropathy	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Stroke	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Tremor	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Psychiatric disorders
Anxiety	1/6 (16.7%)	1	2/6 (33.3%)	2	2/3 (66.7%)	2	2/5 (40%)	2
Depression	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	1/5 (20%)	1
Insomnia	1/6 (16.7%)	1	1/6 (16.7%)	1	1/3 (33.3%)	1	3/5 (60%)	3
Irritability, intermittent	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	1/5 (20%)	1
Renal and urinary disorders
Chronic kidney disease	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Glucosuria	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Hemoglobinuria	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Proteinuria	1/6 (16.7%)	1	2/6 (33.3%)	6	1/3 (33.3%)	1	1/5 (20%)	1
Renal hemorrhage	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Urinary frequency	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Urinary retention	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Urine discoloration	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Respiratory, thoracic and mediastinal disorders
Bronchial obstruction	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Cough	5/6 (83.3%)	5	2/6 (33.3%)	2	2/3 (66.7%)	2	1/5 (20%)	1
Dyspnea	4/6 (66.7%)	8	4/6 (66.7%)	4	2/3 (66.7%)	2	2/5 (40%)	2
Epistaxis	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Hemoptysis	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Hiccups	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Hoarseness	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Hypoxia	1/6 (16.7%)	1	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Pleural effusion	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Pleuritic pain	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
Pneumonitis	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Pneumothorax	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	1/5 (20%)	1
Sore throat	1/6 (16.7%)	1	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Skin and subcutaneous tissue disorders
Alopecia	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1
Erythema multiforme	1/6 (16.7%)	1	0/6 (0%)	0	0/3 (0%)	0	0/5 (0%)	0
itching	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Pruritus	0/6 (0%)	0	1/6 (16.7%)	1	0/3 (0%)	0	0/5 (0%)	0
Rash acneiform	0/6 (0%)	0	0/6 (0%)	0	2/3 (66.7%)	3	0/5 (0%)	0
Vascular disorders
Carotid Stenosis, Rt. interval	0/6 (0%)	0	0/6 (0%)	0	1/3 (33.3%)	1	0/5 (0%)	0
Hypertension	2/6 (33.3%)	2	2/6 (33.3%)	2	2/3 (66.7%)	2	1/5 (20%)	1
Thromboembolic event	0/6 (0%)	0	0/6 (0%)	0	0/3 (0%)	0	1/5 (20%)	1

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.